NCT05055232View on ClinicalTrials.gov

A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

114

Participants

Timeline

Start Date

March 12, 2019

Primary Completion Date

August 15, 2023

Study Completion Date

August 15, 2023

Conditions

ROS1 Rearrangement Non-small Cell Lung CancerALK Rearrangement Non-small Cell Lung Cancer

Interventions

DRUG

XZP-3621

tablets, dosage ranged from 50 mg to 600 mg, quaque die（QD）with the meal.

Trial Locations (1)

Unknown

Shanghai Chest hospital affiliated to Shanghai jiao tong university, Shanghai

All Listed Sponsors

lead

Xuanzhu Biopharmaceutical Co., Ltd.

INDUSTRY

NCT05055232 - A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter